Article: Real-World Tolerability of Intravenous Infusion of NAD+ vs. NR: Clinical Findings

Jan 7, 2026 Clinical Intravenous Pharmacokinetic/Safety

Real-World Tolerability of Intravenous Infusion of NAD+ vs. NR: Clinical Findings

Objectives

To compare commercially administered NAD+ IV and NR IV in humans by evaluating infusion time, tolerability, safety markers, and metabolic outcomes.

Journal

Frontiers in Aging

Key Outcomes

NR IV was well-tolerated, with only mild effects such as temporary tingling or minor cramping, while NAD+ IV caused moderate to severe reactions, including nausea, gastrointestinal distress (vomiting and diarrhea), and elevated heart rate.
NR IV infusions averaged 37 minutes—about 60% faster than NAD+ IV, which required 97 minutes due to side-effect management.
NR IV significantly reduced HbA1c at 30 days, whereas NAD+ IV reduced HDL ("good" cholesterol) and alkaline phosphatase (ALP), though values remained within normal ranges.

Duration

4 days

Dose

500 mg*

*Reconstituted in 500 mL of normal saline prior to administration.

Study Design

Retrospective, observational, comparative pilot study based on electronic medical record review.

A total of 14 participants were included, with 6 receiving NAD+ IV and 8 receiving NR IV.

See Published Study

Clinical

Effects of Nicotinamide Riboside Supplementation on Nerve Fiber Protection and Axon Regeneration: Clinical Findings

Objectives To investigate whether boosting NAD+ levels through nicotinamide riboside (NR) supplementation can protect against or promote regeneration of small somatic sensory axons in human skin f...